Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07132008 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer

StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Building on earlier exploratory work, this study further designs a multi-institutional, prospective, randomized clinical trial to evaluate the efficacy and safety of the combination therapy of the immune checkpoint inhibitor Tislelizumab with CAPOX for neoadjuvant treatment in high-risk locally advanced MSS-type colorectal cancer, as well as its impact on patient outcomes. This study aims to provide new evidence for the clinical practice of treating MSS-type colorectal cancer.
Trial Details
NCT Number NCT07132008
Lead Sponsor First Affiliated Hospital of Guangxi Medical University
Collaborators: The First Affiliated Hospital of Xiamen University, The First Affiliated Hospital of University of South China
Conditions
(from sponsor)		 Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors
Related terms Colonic Neoplasms
Enrollment 94 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov